SCHEMBL273041

SCHEMBL273041

[CH2]CCc1ccc2c(c1)OCO2

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.67
CYP3A4 P08684 5/20 0.59
CYP1A2 P05177 2/20 0.59
MAPT P10636 1/20 0.59
CALM1 P0DP23 2/20 0.57
SLC6A4 P31645 2/20 0.55
SLC6A2 P23975 1/20 0.51
SLC6A3 Q01959 1/20 0.51
CMA1 P23946 1/20 0.51
CYP2D6 P10635 1/20 0.51
ALDH1A1 P00352 2/20 0.50
GAA P10253 1/20 0.50
CYP2C19 P33261 1/20 0.50
MIF P14174 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95457 0.89 TAAR1 (0.62) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL315045 0.88 TAAR1 (0.52) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL108087 0.87 TAAR1 (0.77) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL3030397 0.87 TAAR1 (0.61) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL7425426 0.85 TAAR1 (0.59) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL3023636 0.85 TAAR1 (0.49) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL699637 0.83 CYP3A4 (0.63) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL108050 0.83 CALM1 (0.72) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL11240060 0.82 CYP3A4 (0.64) TAAR1CYP3A4CYP1A2MAPTCALM1
SCHEMBL28886939 0.82 CYP3A4 (0.61) TAAR1CYP3A4CYP1A2MAPTCALM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812133-B Alpha, alpha-difluoroallyl organometallic compound and preparation method and application thereof 南京工业大学 2022-03-11 CN claimed
CN-112812133-A Alpha, alpha-difluoroallyl organometallic compound and preparation method and application thereof 南京工业大学 2021-05-18 CN claimed
CN-110003042-A α, α -difluoroallyl aromatic hydrocarbon compound and preparation method thereof 南京工业大学 2019-07-12 CN claimed
CN-103459382-A Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC 2013-12-18 CN claimed
EP-1716160-B1 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA NV (BE) 2010-12-29 EP claimed
US-20090036409-A1 Novel inhibitors of chymase HAWKINS MICHAEL J 2009-02-05 US claimed
US-7459444-B2 Inhibitors of chymase JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-02 US claimed
US-20080076817-A1 Small Molecule Rotamase Enzyme Inhibitors HAMILTON GREGORY S 2008-03-27 US claimed
JP-2007518807-A 2007-07-12 JP claimed
EP-1716160-A2 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-02 EP claimed
EP-1011650-A1 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS Amgen Inc., (US) 2000-06-28 EP claimed
EP-0998263-A1 PYRROLIDINE DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES GUILFORD PHARMACEUTICALS INC. (US) 2000-05-10 EP claimed
EP-0992492-A1 Small molecule inhibitors of rotamase enzyme activity GUILFORD PHARMACEUTICALS INC. (US) 2000-04-12 EP claimed
WO-1999014998-A2 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS AMGEN INC. (US) 1999-04-01 WO claimed
WO-1998055091-A1 PYRROLIDINE DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES GUILFORD PHARMACEUTICALS INC. (US) 1998-12-10 WO claimed
EP-0769006-A4 GUILFORD PHARM INC (US) 1997-05-28 EP claimed
EP-0769006-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1997-04-23 EP claimed
US-5614547-A Small molecule inhibitors of rotamase enzyme GUILFORD PHARMACEUTICALS INC. (US) 1997-03-25 US claimed
WO-1996040633-A9 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY 1997-02-27 WO claimed
WO-1996040633-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1996-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036409-A1 Novel inhibitors of chymase CMA1, SERPINB1, TPSAB1 TAAR1 1849/4885CYP3A4 939/4885CYP1A2 1199/4885
US-20080076817-A1 Small Molecule Rotamase Enzyme Inhibitors FKBP8, FKBP1A, FKBP2 TAAR1 4509/4885CYP3A4 3508/4885CYP1A2 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.